ES2843277T3 - Aplicación tópica para un anticuerpo anti-VHS - Google Patents

Aplicación tópica para un anticuerpo anti-VHS Download PDF

Info

Publication number
ES2843277T3
ES2843277T3 ES15733409T ES15733409T ES2843277T3 ES 2843277 T3 ES2843277 T3 ES 2843277T3 ES 15733409 T ES15733409 T ES 15733409T ES 15733409 T ES15733409 T ES 15733409T ES 2843277 T3 ES2843277 T3 ES 2843277T3
Authority
ES
Spain
Prior art keywords
hsv
antibody
antigen
binding fragment
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15733409T
Other languages
English (en)
Spanish (es)
Inventor
Michaela Arndt
Jürgen Krauss
Dirk JÄGER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Heidelberg Immunotherapeutics GmbH
Original Assignee
Heidelberg Immunotherapeutics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heidelberg Immunotherapeutics GmbH filed Critical Heidelberg Immunotherapeutics GmbH
Application granted granted Critical
Publication of ES2843277T3 publication Critical patent/ES2843277T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/085—Orthoherpesviridae (F), e.g. pseudorabies virus or Epstein-Barr virus
    • C07K16/087—Herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES15733409T 2014-06-26 2015-06-25 Aplicación tópica para un anticuerpo anti-VHS Active ES2843277T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14174174 2014-06-26
PCT/EP2015/064378 WO2015197763A1 (en) 2014-06-26 2015-06-25 Topical application for an anti-hsv antibody

Publications (1)

Publication Number Publication Date
ES2843277T3 true ES2843277T3 (es) 2021-07-16

Family

ID=51032986

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15733409T Active ES2843277T3 (es) 2014-06-26 2015-06-25 Aplicación tópica para un anticuerpo anti-VHS

Country Status (13)

Country Link
US (2) US11267871B2 (https=)
EP (1) EP3160997B1 (https=)
JP (1) JP6649284B2 (https=)
KR (1) KR102622280B1 (https=)
CN (2) CN106488931B (https=)
AU (1) AU2015279212B2 (https=)
CA (1) CA2950489C (https=)
ES (1) ES2843277T3 (https=)
NZ (1) NZ726168A (https=)
RU (1) RU2703903C2 (https=)
SG (1) SG11201610320RA (https=)
WO (1) WO2015197763A1 (https=)
ZA (1) ZA201607813B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3055555A1 (en) 2016-03-11 2017-09-14 Scholar Rock, Inc. Tgf.beta.1-binding immunoglobulins and use thereof
EP3566749A4 (en) * 2017-01-09 2020-09-23 Medshine Discovery Inc. THIAZOLE DERIVATIVE AND USES OF IT
US11472867B2 (en) 2017-08-30 2022-10-18 Km Biologics Co., Ltd. Anti-HSV GB monoclonal antibody or antigen-binding fragment thereof
US12247066B2 (en) 2018-08-28 2025-03-11 Pontificia Universídad Católica de Chile Monoclonal antibody 14F5F6 or fragment thereof, that specifically recognizes herpes simplex virus 1 and 2
WO2020041911A1 (es) * 2018-08-28 2020-03-05 Pontificia Universidad Catolica De Chile Anticuerpo monoclonal 11b2c7 o fragmento del mismo, que reconoce específicamente virus herpes simple 1 y 2
EP3941524A1 (en) * 2019-03-19 2022-01-26 Albert Einstein College of Medicine Monoclonal antibodies for prevention and treatment of herpes simplex viral infections
WO2022002802A1 (en) * 2020-06-29 2022-01-06 Glaxosmithkline Biologicals Sa HSV gEgI HETERODIMER ANTIBODIES
TW202406932A (zh) 2020-10-22 2024-02-16 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
US20260001939A1 (en) * 2022-03-02 2026-01-01 Heidelberg Immunotherapeutics Gmbh Vaccine comprising an antibody or an fc-containing fusion protein comprising an fc part of an antibody
TW202426053A (zh) * 2022-09-02 2024-07-01 聯合生物製藥股份有限公司 單純皰疹病毒感染的治療
EP4727967A1 (en) 2023-06-16 2026-04-22 Heidelberg ImmunoTherapeutics GmbH Novel anti-hsv antibody

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995018634A1 (en) * 1994-01-04 1995-07-13 The Scripps Research Institute Human monoclonal antibodies to herpes simplex virus and methods therefor
EP1222281B1 (en) * 1999-09-30 2006-11-15 University of Washington Immunoligically significant herpes simplex virus antigens
EA013564B1 (ru) * 2000-08-03 2010-06-30 Терапеутик Хьюман Поликлоналз Инк. Гуманизированный иммуноглобулин и содержащая его фармацевтическая композиция
US20070274997A1 (en) 2003-07-25 2007-11-29 Anthony Simmons Compositions and Methods for Herpes Simplex Prophylaxis and Treatment
US6984492B2 (en) * 2003-09-05 2006-01-10 Talecris Biotherapeutics, Inc. Methods and compositions for treating herpes infections
WO2010129033A2 (en) 2009-04-29 2010-11-11 Calmune Corporation Modified antibodies for passive immunotherapy
PL2248825T3 (pl) * 2009-05-04 2013-04-30 Ribovax Biotechnologies Sa Fragmenty przeciwciała wiążące antygen do zastosowania w leczeniu i diagnozowaniu chorób oczu
EP2308895A1 (en) * 2009-10-01 2011-04-13 Universität Duisburg-Essen Anti-HSV antibody
EP2694542A4 (en) * 2011-04-08 2014-10-08 Univ Duke HERPES SIMPLEX VIRUS

Also Published As

Publication number Publication date
RU2017102387A (ru) 2018-07-26
CN106488931B (zh) 2021-12-28
US20220169705A1 (en) 2022-06-02
EP3160997A1 (en) 2017-05-03
JP6649284B2 (ja) 2020-02-19
RU2017102387A3 (https=) 2018-07-26
WO2015197763A1 (en) 2015-12-30
EP3160997B1 (en) 2020-10-28
CN106488931A (zh) 2017-03-08
JP2017520572A (ja) 2017-07-27
KR102622280B1 (ko) 2024-01-08
AU2015279212A2 (en) 2017-04-27
CA2950489C (en) 2022-09-20
NZ726168A (en) 2022-05-27
CN114306596A (zh) 2022-04-12
AU2015279212A1 (en) 2016-12-01
RU2703903C2 (ru) 2019-10-22
BR112016030422A2 (pt) 2017-10-24
CA2950489A1 (en) 2015-12-30
AU2015279212B2 (en) 2020-08-20
US11267871B2 (en) 2022-03-08
US20170152304A1 (en) 2017-06-01
SG11201610320RA (en) 2017-01-27
KR20170020423A (ko) 2017-02-22
ZA201607813B (en) 2018-05-30

Similar Documents

Publication Publication Date Title
ES2843277T3 (es) Aplicación tópica para un anticuerpo anti-VHS
ES2715787T3 (es) Anticuerpo anti-VHS
JP6654967B2 (ja) Ｉｌ−３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物
CN104995212A (zh) 以il-4r拮抗剂治疗特应性皮炎的方法
ES2992409T3 (es) Métodos de tratamiento de la psoriasis en placas de nueva aparición usando antagonistas de IL-17
KR20180084045A (ko) 비형 간염 표면 항원에 대한 항체 및 그의 용도
CN108472372B (zh) 结合不动杆菌的抗体结合剂及其用途
WO2016115092A1 (en) Methods for targeting host vascular mechanism for therapeutic protection against hemorrhagic fever
JP2025537301A (ja) Ｓａｒｓ－ｃｏｖ－２を標的とする抗原結合分子
KR20250107839A (ko) 심혈관계 질환의 치료 방법
US20250296988A1 (en) Combination therapy
JP2019517480A (ja) 脊髄損傷及び疼痛を処置するための抗ＲＧＭａ（Ｒｅｐｕｌｓｉｖｅ Ｇｕｉｄａｎｃｅ Ｍｏｌｅｃｕｌｅ Ａ）アンタゴニスト抗体
BR112016030422B1 (pt) Anticorpo anti-hsv e composição farmacêutica compreendendo o referido anticorpo
US20210332112A1 (en) Stabilized pertussis antibodies with extended half-life
EP4727967A1 (en) Novel anti-hsv antibody
TW202337497A (zh) 鼻內調配物及抗sars-cov-2棘蛋白抗體
WO2025250861A1 (en) Broadly neutralizing anti-hcmv antibodies and uses thereof
TW202547886A (zh) 用於治療ｃ１ｓ介導的疾病和病症的組成物、劑量和方法
TW202611068A (zh) 頭頸部異位性皮膚炎的治療